Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of…
“There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they…
“We can also look at the timing of exposure to urology. Does early exposure spark interest in urology, or does delayed introduction to the field…
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective…
“In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it’s really an unknown whether comprehensive SBRT or other…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for…
“We are very excited here at Potomac Urology to be the first center in the United States, and just the second center internationally, to offer…
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
“A key piece of the guideline is that we need to offer radiation at a PSA of 0.5 ng/mL or lower and maybe even, for…
